News | January 27, 2015

NewYork-Presbyterian Hospital/Columbia University Medical Center Participate in HeartMate III Trial

Device designed to take over pumping ability of weakened left ventricle

Thoratec, HeartMate III, VAD, NewYork Presbyterian, trial, ventricular assist

HeartMate III image courtesy of Thoratec

January 27, 2015 — NewYork-Presbyterian Hospital/Columbia University Medical Center is one of a select group of medical centers participating in a clinical trial of a new device for advanced heart failure patients, the Thoratec HeartMate III Left Ventricular Assist System (LVAS). The device is designed to supplement the heart’s pumping function in patients with left-sided heart failure.

Some 5 million people in the United States are afflicted with congestive heart failure. About 50 percent of people who develop heart failure die within five years of diagnosis.

Doctors at NewYork-Presbyterian/Columbia are evaluating the performance and safety of the HeartMate III in subjects with advanced heart failure. They will help determine the device’s efficacy as a long-term support option for patients who are not candidates for heart transplantation and as a short-term support option for patients awaiting a heart transplant. If successful, the device will improve heart function, blood flow and quality of life for these patients.

Sometimes called a “heart pump” or “LVAD,” the HeartMate III is designed to take over the pumping ability of the weakened heart's left ventricle, which pumps oxygen-rich blood from the lungs throughout the body.

The device is implanted above the diaphragm, immediately next to the heart, and attached to the aorta. A centrifugal blood pump is implanted directly onto the patient's heart, leaving natural circulation in place. In addition, the patient wears an external, wearable controller and battery system to power the pump.

The device offers a number of improvements over its predecessors, including smaller size and a design that mimics the natural pulse rate. The device is fully magnetically levitated, so the parts “float” rather than rub together, which should make it more durable.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init